Get started
Author

Ana Medina

Observed names: A Medina Colmenero, A. Medina, A. Medina-Colmenero, ANA MEDINA, Ana Medina Colmenero, Ana Medina-Colmenero, Medina Colmenero, Ana
ORCID: 0000-0003-2961-1529
Observed ORCID: 0000-0003-2961-1529
OpenAlex ID: A5016855969
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
2019 · Elena Castro, Nuria Romero-Laorden, et al. · Journal of Clinical Oncology · 388
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
2018 · Vincenza Conteduca, Anuradha Jayaram, et al. · European Urology · 85
PDF
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting
2017 · Javier Puente, Enrique Grande, et al. · Therapeutic Advances in Medical Oncology · 73
PDF
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
2020 · D.J. Khalaf, I.M. Aragón, et al. · Annals of Oncology · 48
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
2021 · J. Ruiz-Bañobre, A. Molina-Díaz, et al. · ESMO Open · 47
PDF
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
2021 · Xavier Garcia del Muro, Begoña P. Valderrama, et al. · Journal of Clinical Oncology · 35
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
2019 · Vincenza Conteduca, Elena Castro, et al. · European Journal of Cancer · 35
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al. · Clinical Cancer Research · 21
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
2017 · J. Bellmunt, J.M. Kerst, et al. · Annals of Oncology · 21
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
2023 · Nuria Romero-Laorden, David Lorente, et al. · European Urology Oncology · 19
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer
2020 · David Lorente, Elena Castro, et al. · European Urology · 11
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
2024 · Urbano Anido-Herranz, Ovidio Fernandez-Calvo, et al. · Frontiers in Oncology · 10
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
2023 · Anagha Gogate, Bryan Bennett, et al. · Cancers · 8
PDF
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
2020 · M. Andres Cuellar, Ana Medina, et al. · Journal of Clinical Oncology · 7
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)
2016 · Jorge García, Lucia Santomé, et al. · Current Oncology Reports · 7
Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023 · SANTIAGO AGUIN, ALBERTO CARRAL, et al. · Cancer Diagnosis & Prognosis · 5
PDF
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
2018 · U. Anido-Herranz, N. Fernández-Núñez, et al. · Clinical & Translational Oncology · 5
PDF
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria
2022 · A. Triguero, B. Xicoy, et al. · Leukemia Research · 4
590P PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration resistant prostate cancer (mCRPC)
2021 · E. Castro, R. Lozano Mejorada, et al. · Annals of Oncology · 4
PDF
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
2019 · Rebeca Lozano, Elena Castro, et al. · Journal of Clinical Oncology · 4
Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck – ReCisTT study
2024 · Ana Varges Gomes, Gilberto Castro, et al. · Frontiers in Oncology · 3
PDF
Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)
2019 · I.M. Aragon, Y. Cendón, et al. · Annals of Oncology · 3
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
2025 · Cristina Suárez, Òscar Reig Torras, et al. · Clinical Genitourinary Cancer · 2
Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).
2018 · Vincenza Conteduca, Anuradha Jayaram, et al. · Journal of Clinical Oncology · 2
Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.
2018 · Rebeca Lozano, Nuria Romero-Laorden, et al. · Journal of Clinical Oncology · 2
Works count: 67
Citation count: 858
H-index: 11
I10-index: 12
Year
Topic
Type